“The value of AI applications in medical care can only be confirmed when professional guidelines provide recommendations for their use in specific clinical settings and patient populations,” wrote Gerold Porenta, MD, PhD, in a recent commentary published in the Journal of Nuclear Medicine.
Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).
The U.S. Nuclear Regulatory Commission (NRC) opened a 30-day public comment period seeking feedback on its draft document outlining training and experience requirements for administrating radiopharmaceuticals requiring a written directive.
The joint statement—published in Thyroid—was put out by American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association.
Johns Hopkin’s researchers have created a PET-based approach that can direct cancer drugs to precise points in the brains of mice, according to a study published in the May 1 edition of the Journal of Nuclear Medicine. If proven effective in humans, the researchers believe their technique could help patients with difficult brain tumors, such as glioblastomas.
The prospective single-center study, published April 30 in the American Journal of Roentgenology, adds more weight to the growing literature suggesting PSMA-11’s vital role in prostate cancer management.
“With imaging, we’ll be able to identify vulnerable plaque, deliver treatment directly to it, and see whether the treatment is effective," said award recipient Yongjian Liu, PhD, with Washington University in St. Louis.
18F-DCFPyL PSMA PET/CT imaging accurately localized biochemically recurrent prostate cancer and prompted clinicians to change their management plans in more than 80% of patients, according to a recent study in the Journal of Nuclear Medicine.